Please assess the completion status of the following clinical trial:

Trial Title: Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females with histologically confirmed metastatic clear cell RCC~* Measurable disease according to Response Criteria for Solid Tumors (RECIST)~* No prior systemic cytotoxic chemotherapy~* Subjects who have received either no prior therapy for RCC, systemic immunotherapy only (such as interleukin-2 or interferon), or one agent targeting VEGF or a VEGFR (eg, bevacizumab, sorafenib, or sunitinib malate) may be enrolled~* ECOG performance status of 0 or 1~* Life expectancy ≥3 months~* Adequate organ and marrow function~* No other malignancies within 5 years~* Signed informed consent~Exclusion Criteria:~* Radiation to ≥25% of bone marrow within 30 days of XL999 treatment~* Subjects who have received systemic anticancer therapy within 30 days of XL999 treatment~* Subjects who have not recovered to grade ≤1 or to within 10% of baseline from adverse events due to medications administered \>30 days prior to study enrollment~* History of or known brain metastases, current spinal cord compression or carcinomatous meningitis~* Uncontrolled and/or intercurrent illness~* Pregnant or breastfeeding females~* Known HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).